Magnesium for Migraines: Benefits, Dosage, and What the Research Actually Shows

Why Magnesium and Migraines Are Deeply Connected

Magnesium is the fourth most abundant mineral in the human body, involved in over 600 enzymatic reactions—including neurotransmitter regulation, vascular tone, and cortical excitability. All three of those pathways sit at the center of migraine pathophysiology, which is precisely why low magnesium status is found so consistently in people who experience frequent migraines.

Research published in Cephalalgia found that intracellular magnesium levels were significantly lower in migraine patients during attacks compared to controls, and that low magnesium is associated with cortical spreading depression—the wave of neuronal suppression believed to trigger the migraine cascade (Mauskop & Altura, Cephalalgia 1994; PMID: 7987395). A later review confirmed that roughly 50% of migraine patients show measurable magnesium deficiency during an acute attack (Mauskop & Varughese, Journal of Neural Transmission 2012; PMID: 22426836).

The mechanism is multi-pronged. Magnesium blocks NMDA receptors, which limits the neuronal overactivation that propagates migraine pain. It also inhibits platelet aggregation, modulates serotonin receptors, and reduces substance P—a neuropeptide strongly associated with pain amplification. In short, magnesium acts on several levers that other migraine interventions target only one at a time.

For anyone tracking optimal magnesium glycinate dosage for sleep or stress, the migraine application uses similar doses but is supported by its own distinct body of clinical evidence.

The Clinical Evidence: What Trials Actually Show

The landmark randomized, double-blind, placebo-controlled trial by Peikert et al. (1996) enrolled 81 patients and found that 600 mg/day of trimagnesium dicitrate reduced migraine attack frequency by 41.6% compared to 15.8% in the placebo group over 12 weeks (Cephalalgia 1996; PMID: 8792038). The treatment group also saw meaningful reductions in migraine duration and pain intensity.

A second RCT by Köseoglu et al. (2008) using 600 mg/day of magnesium citrate over 16 weeks demonstrated significant reductions in both attack frequency and severity, with tolerability as the primary limiting factor at higher doses (Magnesium Research 2008; PMID: 18705538).

For menstrual migraines specifically—a subtype driven partly by the sharp drop in estrogen and corresponding magnesium depletion before menstruation—a trial by Facchinetti et al. (1991) showed that 360 mg/day of magnesium pyrrolidone carboxylic acid significantly reduced the number of days with headache and total pain index compared to placebo (Headache 1991; PMID: 1860787).

These results were strong enough that the American Headache Society and the American Academy of Neurology issued a Grade B recommendation for magnesium in migraine prevention, placing it alongside riboflavin and coenzyme Q10 as a first-line nutraceutical option (Holland et al., Neurology 2012; PMID: 22529202).

It's also worth noting that intravenous magnesium sulfate has been studied as an acute abortive treatment. A 2014 systematic review found IV magnesium provided statistically significant pain relief in acute migraine in the emergency setting, particularly in patients with aura (Shahrami et al., Journal of Emergency Medicine 2015; PMID: 25529267).

Magnesium Glycinate vs Magnesium Oxide: Which One Actually Gets Absorbed?

Not all magnesium supplements are equal—and the form matters enormously for both absorption and tolerability, especially at the 400–600 mg elemental doses used in migraine trials.

Magnesium oxide is the most widely sold form in pharmacies. It has a high elemental magnesium content by weight (~60%), but its bioavailability is notoriously poor—estimated at around 4% in some absorption studies. A comparative study by Firoz & Graber (2001) found magnesium oxide was significantly less bioavailable than magnesium chloride, magnesium lactate, and magnesium aspartate (Magnesium Research 2001; PMID: 11794633). At high doses, the unabsorbed magnesium pulls water into the gut and causes diarrhea—making dose escalation to therapeutic levels difficult.

Magnesium glycinate (magnesium bound to the amino acid glycine) offers superior bioavailability. Because it is absorbed via amino acid transporters in addition to passive diffusion, it bypasses the saturable transport mechanisms that limit inorganic forms. Glycine itself is calming—it acts as an inhibitory neurotransmitter in the CNS—which adds a secondary benefit for migraine sufferers who often experience heightened sensory sensitivity. Magnesium glycinate is significantly less likely to cause loose stools at therapeutic doses, making dose compliance easier over the 8–12-week window required to see preventive benefits.

For migraine prevention, magnesium glycinate is the preferred form for long-term oral supplementation: effective elemental dose delivery at 300–400 mg/day with minimal GI side effects. Ones includes Magnesium Glycinate in its Magnesium Complex system blend and as a standalone ingredient, calibrated to the clinical dosing range associated with neurological and vascular outcomes.

Magnesium Glycinate vs Magnesium Threonate: Which Is Better for Neurological Conditions?

This comparison comes up frequently when people research magnesium for migraines, and the answer depends on what outcome you're prioritizing.

Magnesium L-threonate (MgT) was developed specifically to cross the blood-brain barrier more efficiently than other forms. Animal research published in Neuron (2010) by Liu et al. showed that MgT increased brain magnesium concentrations significantly more than magnesium sulfate and improved synaptic plasticity and memory (Liu et al., Neuron 2010; PMID: 20152836). Human trials have focused primarily on cognitive outcomes—memory, attention, and anxiety—rather than migraine frequency specifically.

Magnesium glycinate, by contrast, has a larger evidence base for migraine-adjacent conditions: anxiety reduction, sleep quality, and general neurological function. Its calming glycine component may help with the sleep disruption and heightened stress reactivity that commonly precede migraine attacks. For readers already exploring clinical evidence for ashwagandha as a cortisol management tool, pairing it with magnesium glycinate addresses a complementary pathway.

For migraine prevention specifically, magnesium glycinate is the more evidence-aligned choice based on existing oral supplementation trials. Magnesium threonate may be the better choice if cognitive symptoms—brain fog, memory disruption during prodrome—are the primary complaint. Some practitioners combine both forms at lower individual doses to target different compartments simultaneously.

Magnesium Taurate vs Magnesium Glycinate: A Head-to-Head Look

Magnesium taurate is magnesium bound to taurine—an amino acid with established cardiovascular and neurological effects. Taurine is an endogenous inhibitory neurotransmitter, modulates GABA receptors, and has been shown to reduce blood pressure through vascular relaxation (Militante & Lombardini, Nutritional Neuroscience 2002; PMID: 12168689). This makes magnesium taurate particularly relevant for migraines driven by vascular dysregulation or in patients who also present with hypertension or cardiac arrhythmia.

In terms of bioavailability, both magnesium glycinate and magnesium taurate are well-absorbed chelated forms—both far superior to oxide. The real difference is the co-factor:

• Glycine adds inhibitory neurotransmitter support, promotes sleep quality, and reduces cortisol reactivity
• Taurine adds cardiovascular protection, GABAergic calming, and antioxidant effects

For a migraine sufferer with co-occurring anxiety and poor sleep, magnesium glycinate may be the better choice. For a migraine patient who also tracks heart rate variability on a wearable and sees irregular patterns before headache onset, magnesium taurate's cardiovascular profile is worth considering. Ones' AI health practitioner evaluates exactly this kind of multi-system data—wearable HRV trends alongside lab magnesium levels—to determine which form belongs in a personalized formula.

For a deeper comparison of how taurate and glycinate compare in broader stress and cardiovascular contexts, the omega-3 EPA DHA ratio guide offers useful context on multi-system supplementation strategy.

Optimal Dosing Protocol for Magnesium Migraine Prevention

The clinical trials that demonstrated efficacy used doses ranging from 360 mg to 600 mg of elemental magnesium per day. Here's a practical starting framework:

1. Start at 200–300 mg elemental magnesium (as glycinate or citrate) in the evening with food
2. Titrate up by 100 mg every 1–2 weeks based on GI tolerance
3. Target 400–500 mg/day elemental as the maintenance dose for migraine prevention
4. Allow 8–12 weeks before assessing efficacy—magnesium repletion takes time to normalize intracellular levels
5. Track headache frequency, duration, and intensity using a headache diary or wearable data integration
6. Test serum or RBC magnesium at baseline and 90 days—RBC magnesium (red blood cell magnesium) is a more accurate marker than serum alone

Note that individuals with kidney disease should consult a physician before supplementing magnesium, as impaired renal clearance can lead to accumulation.

For menstrual migraine, consider cycling magnesium intake with your cycle: 360 mg/day starting 15 days before the expected onset of menstruation, based on the Facchinetti et al. protocol.

What This Means for Your Formula: How Ones Addresses Migraine Prevention

Ones takes the guesswork out of magnesium selection by analyzing your blood panel, wearable data, and health history before recommending any ingredient or form. If your RBC magnesium is low, if your HRV trends show pre-headache autonomic disruption, or if your health history flags frequent migraines, the Ones AI health practitioner builds a formula calibrated to your specific deficit—not a generic multivitamin that lumps in 80 mg of oxide and calls it done.

Three specific Ones ingredients are most relevant for migraine prevention:

• Magnesium Glycinate (as part of the Magnesium Complex system blend): Included at doses within the 300–500 mg elemental range demonstrated in clinical trials, with superior GI tolerability for long-term adherence
• CoQ10/Ubiquinol (200 mg): A Grade B evidence-backed migraine preventive in its own right. A double-blind RCT by Sándor et al. (2005) found 300 mg/day of CoQ10 reduced migraine frequency by 47.6% compared to 14.4% for placebo (Neurology 2005; PMID: 15728298). Ones uses the ubiquinol form for superior bioavailability
• Riboflavin (Vitamin B2): Another AAN Grade B nutraceutical for migraine. Schoenen et al. (1998) showed 400 mg/day reduced attack frequency by 50% in responders (Neurology 1998; PMID: 9484373). Ones includes riboflavin at this clinically validated dose as an individual ingredient option

The combined protocol of magnesium + CoQ10 + riboflavin represents the most evidence-dense nutraceutical approach to migraine prevention, and it's one that platforms like Thorne offer in fixed formulas—but without personalization to your actual lab levels or wearable patterns. Ones builds this stack dynamically around your data, adjusting doses within a 6, 9, or 12-capsule daily plan based on your total formula load and current deficiencies.

If you're also managing energy, sleep, or stress alongside migraines, vitamin D3 and K2 synergy is another area where personalized dosing makes a measurable difference in outcomes.

Key Takeaways

• Magnesium deficiency affects ~50% of migraine patients during acute attacks and is a well-documented driver of cortical spreading depression, NMDA receptor overactivation, and vascular dysregulation
• Clinical trials support 400–600 mg/day of elemental magnesium for migraine prevention, with a 41.6% reduction in attack frequency demonstrated in the gold-standard Peikert et al. RCT
• Magnesium glycinate is the preferred form for long-term oral supplementation due to its superior bioavailability, gentle GI profile, and calming glycine co-factor—far better suited for therapeutic dosing than magnesium oxide
• Magnesium threonate targets brain magnesium more precisely and may benefit migraine patients with prominent cognitive or prodromal neurological symptoms, while magnesium taurate suits those with cardiovascular co-morbidities
• Allow 8–12 weeks for magnesium repletion to reflect in migraine frequency outcomes; use RBC magnesium testing (not serum alone) to track progress accurately
• Combining magnesium with CoQ10 (200–300 mg ubiquinol) and riboflavin (400 mg) represents the highest-evidence nutraceutical stack for migraine prevention—all three carry an AAN Grade B recommendation and can be precisely calibrated in a personalized Ones formula